Penumbra (PEN) Stock Forecast & Price Target

$201.50

+5.92 (+3.03%)

(As of 12:59 PM ET)

Penumbra - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 14 Analyst Ratings

Based on 14 Wall Street analysts who have issued ratings for Penumbra in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 14 analysts, 5 have given a hold rating, 8 have given a buy rating, and 1 has given a strong buy rating for PEN.

Consensus Price Target

$208.00
3.23% Upside

High Forecast	$263.00
Average Forecast	$208.00
Low Forecast	$150.00

According to the 14 analysts' twelve-month price targets for Penumbra, the average price target is $208.00. The highest price target for PEN is $263.00, while the lowest price target for PEN is $150.00. The average price target represents a forecasted upside of 3.23% from the current price of $201.50.

Type	Current Forecast 9/20/23 to 9/19/24	1 Month Ago 8/21/23 to 8/20/24	3 Months Ago 6/22/23 to 6/21/24	1 Year Ago 9/20/22 to 9/20/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	6 Buy rating(s)	7 Buy rating(s)	11 Buy rating(s)
Hold	5 Hold rating(s)	5 Hold rating(s)	3 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$208.00	$193.60	$300.64	$324.38
Forecasted Upside	3.23% Upside	7.50% Upside	21.21% Upside	20.97% Upside

Central Bank Abandons USD (Ad)

Startling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold.

Click here now to get your free 'Protect Your Wealth' Guide.

PEN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

PEN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Penumbra Stock vs. The Competition

Type	Penumbra	Medical Companies	S&P 500
Consensus Rating Score	2.71	2.77	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	6.35% Upside	1,006.90% Upside	7.94% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/17/2024	Stifel Nicolaus 4 of 5 stars		Initiated Coverage	Buy	$238.00	+27.23%
9/3/2024	Leerink Partnrs 0 of 5 stars	M. Kratky Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
9/3/2024	Leerink Partners 1 of 5 stars		Initiated Coverage	Outperform	$263.00	+29.99%
8/28/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$187.00 ➝ $224.00	+11.98%
8/22/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Wuensch Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$178.00 ➝ $200.00	+1.31%
7/31/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$231.00 ➝ $180.00	+6.93%
This Crypto Is Set to Explode in September (Ad) With thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make HUGE gains. Now, I'm about to reveal the #1 crypto for September 2024. Go here to get full details on this crypto now.
7/31/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$289.00 ➝ $205.00	+20.47%
7/31/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$230.00 ➝ $200.00	+16.26%
7/31/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$272.00 ➝ $176.00	+18.65%
7/31/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Hold
7/31/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$260.00 ➝ $200.00	+15.77%
7/31/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Biegelsen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$289.00 ➝ $150.00	-13.17%
7/15/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$235.00 ➝ $210.00	+9.96%
2/23/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Neutral	$284.00 ➝ $250.00	-4.81%
6/26/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$325.00 ➝ $376.00	+13.18%
5/3/2023	58.com Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
10/12/2022	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$230.00	+27.86%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 01:27 PM ET.

PEN Forecast - Frequently Asked Questions

What is Penumbra's forecast for 2024?: According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for Penumbra is $208.00, with a high forecast of $263.00 and a low forecast of $150.00.
Should I buy or sell Penumbra stock right now?: 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last twelve months. There are currently 5 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PEN shares.
Does Penumbra's stock price have much upside?: According to analysts, Penumbra's stock has a predicted upside of 11.19% based on their 12-month stock forecasts.
Has Penumbra been upgraded or downgraded by Wall Street analysts recently?: Over the previous 90 days, Penumbra's stock had 2 downgrades and 1 upgrade by analysts.
What analysts cover Penumbra?: Penumbra has been rated by research analysts at BTIG Research, Canaccord Genuity Group, Citigroup, Leerink Partners, Leerink Partnrs, Morgan Stanley, Needham & Company LLC, Piper Sandler, Robert W. Baird, Royal Bank of Canada, Stifel Nicolaus, Truist Financial, and Wells Fargo & Company in the past 90 days.
Do Wall Street analysts like Penumbra more than its competitors?: Analysts like Penumbra less than other "medical" companies. The consensus rating score for Penumbra is 2.71 while the average consensus rating score for "medical" companies is 2.77. Learn more on how PEN compares to other companies.